Project Name: Midlands Medical Partnership (MMP) Lipid Project
The main objective of the CWP is to improve the quality of care for patients and support the early identification, review, and medical optimisation of patients with atherosclerotic cardiovascular disease (ASCVD) who are at high risk of cardiovascular events and who are not achieving lipid levels as specified in national and/or local guidance, in response to the needs of the CW Partner.
- CWP kick-off meeting.
- Baseline data collated to measure project outcomes against.
- Clinical and operational pathway, policy and protocol creation.
- Confirmation of readiness to begin the clinical activity.
- Project progress check in meetings, including latest clinical activity data.
- Analysis of CWP data, submission of final CWP report, submission of outcomes summary.
- CWP wrap up meeting.
For the Patient:
Improved access to lipid management care leading to optimal diagnosis and management of ASCVD treatments.
Enhanced experience around ASCVD with ongoing management of the condition.
Improved access to appropriate medication for suitable patients to preserve health and prevent long-term events.
Easier access to lipid management care closer to home in the Primary Care setting.
The additional capacity will provide additional time and support from GP Super Partnership HCP with their lipid management, focusing on patients who may have previously not attended GP appointment or been lost to follow-up. Thus, levelling health inequalities within the GP Super Partnership.
For the CW Partner:
Increased proportion of ASCVD patients reviewed by primary care.
Increased proportion of ASCVD patients receiving expert and timely review closer to home.
Reduction in ASCVD referral rates to secondary care.
Increased proportion of patients receiving guideline-directed pharmacotherapy.
Insight into benefits of primary care pharmacist led lipid management clinics in primary care.
Support aligned to NHS Long Term Plan, CVDPREVENT, and Network Contract DES.
Insight on the appropriate use of ASCVD licensed medicines in line with NICE guidelines, including Novartis’s medicine.
Enhanced reputation and supporting Novartis’ vision that no patient should have to wait for an extraordinary life, by supporting high quality Collaborative Working with healthcare organisations which addresses the problem of health inequalities.
Ethical, professional, and transparent relationship between Novartis and the Healthcare Organisation.
Start Date & Duration: September 2023 for 9 months